迈瑞医疗：国际收入占比提升至约50%

Core Viewpoint - Company aims to increase international revenue to approximately 50% of total revenue by mid-2025, with a focus on expanding its presence in overseas markets and enhancing local production capabilities [1] Revenue Breakdown - As of now, international revenue accounts for about 50% of the company's overall revenue, with international in vitro diagnostics contributing 29% and international animal healthcare and minimally invasive surgery accounting for 12% of international revenue [1] Future Development Direction - The company plans to maintain a strong focus on international markets, particularly in developing countries, which are expected to grow rapidly [1] - The long-term goal is for international revenue to reach 70% of total revenue, supported by deeper localization efforts and a robust response to changing international conditions [1] Market Position and Strategy - Despite having a market share of only 2-3% in overseas markets, the company believes that the international market potential is significantly larger than the domestic market [1] - The company has established localized production bases in 14 countries, with 11 already in operation, to meet high-end customer demands and comply with local government requirements [1] Stock Performance Insights - Stock price fluctuations are influenced by various factors including company performance, macroeconomic conditions, industry policies, and market sentiment, rather than a single factor [1] - The company expresses confidence in its ability to deliver stable operating performance and healthy profit levels, which are essential for long-term investor returns and market recognition [1]